GlassScriptPhysician profile
Erin Regalado
NPI 1770320053
$456.26
in general payments reported to CMS, 2019-2025
12 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $96.15 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $456.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $62.56 | 2024-2025 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.49 | 2024-2025 | Relistor |
| Globus Medical, INC. | $58.47 | 2025 | Senza |
| Protega Pharmaceutials INC | $54.91 | 2025 | Roxybond |
| Forte Bio-Pharma LLC | $48.64 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Averitas Pharma INC. | $36.10 | 2025 | Qutenza |
| Abbvie INC. | $32.14 | 2025 | |
| Tonix Medicines, INC. | $25.46 | 2025 | Tonmya |
| Saluda Medical Americas, INC. | $25.00 | 2025 | Evoke |
| Bioventus LLC | $24.40 | 2024 | Durolane |
| Lundbeck LLC | $14.20 | 2025 | Vyepti |
| Valinor Pharma, LLC | $13.89 | 2025 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Regalado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.